Uncategorized

BMS welcomes new multiple myeloma drug as generics batter current portfolio

Published

on

The FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in the second quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version